Form 4: Pasithea Director Boosts Stake with $100K Stock Purchase

Pasithea Therapeutics Corp. Director and 10% owner Lawrence Steinman acquired 133,333 shares of common stock at $0.75 per share, increasing his direct beneficial ownership to 199,691 shares.

Summary

• Lawrence Steinman, a Director and 10% owner of Pasithea Therapeutics Corp. (KTTA), purchased 133,333 shares of common stock.
• The transaction occurred on November 28, 2025, at a price of $0.75 per share.
• This purchase was made pursuant to a Rule 10b5-1(c) trading plan.
• Following this transaction, Mr. Steinman directly beneficially owns 199,691 shares of Pasithea Therapeutics Corp. common stock.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a significant insider purchase by a director and 10% owner, indicating strong confidence in the company's future.

Positives

• A Director and 10% owner, Lawrence Steinman, increased his stake in the company, signaling confidence in future prospects.
• The purchase of 133,333 shares at $0.75 per share represents a significant investment of approximately $100,000 by an insider.

Future Outlook

The filing itself does not contain forward-looking statements or guidance, as it is a report of a past insider transaction.

Industry Context

Insider buying, particularly by a director and significant shareholder, can be interpreted by the market as a positive signal regarding the company's valuation and future prospects within the biotechnology and pharmaceutical industry. It suggests that those closest to the company believe its stock is undervalued or poised for growth.

Comparison to Industry Standards

• Insider purchases, especially by directors or 10% owners, are generally viewed favorably across all industries as they align management's interests with those of shareholders. While specific comparable companies or projects are not detailed in this filing, such a transaction typically outperforms general market sentiment when it occurs at a perceived low point or before significant positive news.

Related Party Transactions

• The transaction involves a director and 10% owner of Pasithea Therapeutics Corp. purchasing shares, which is a related party transaction reported under Section 16(a) of the Securities Exchange Act of 1934.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator, potentially increasing confidence in the company's stock.
• The transaction aligns the interests of a key director and 10% owner more closely with those of other shareholders.

Key Dates

Recommendation

The significant insider purchase by a director and 10% owner, Lawrence Steinman, at $0.75 per share, signals strong confidence in Pasithea Therapeutics Corp.'s valuation and future prospects. Such a move by a well-informed insider often precedes positive developments or indicates a belief that the stock is undervalued, making it a compelling 'buy' signal for seasoned investors.

Keywords

Pasithea Therapeutics, KTTA, Insider Buying, Stock Purchase, Director, Ownership Change, SEC Form 4, Biotechnology, Pharmaceuticals